The Biggest Victims of the Patent Cliff in 2014
The patent cliff has been the biggest challenge facing the pharmaceutical industry as of late. It's already taken a huge bite out of some big pharma firms' financials: Top drugmaker Pfizer has seen its sales taken down this year thanks to the patent loss of former top-selling compound Lipitor, which has lost around half of its revenue year-over-year through the first nine months of 2013. In 2014, two companies are facing even bigger potential losses than Pfizer.
Who's up to bat in the new year? Look no further than Eli Lilly and AstraZeneca . These two companies are facing tough times ahead with the loss of patent protection on their respective star drugs Cymbalta and Nexium, and the resulting fallout could cost the companies billions of dollars of revenue -- and investors a big hit to their portfolio.
But can Eli Lilly and AstraZeneca beat the patent cliff next year? Find out in the video below, as Fool contributor Dan Carroll takes you through the daunting hurdles these two big pharma firms face -- and whether they can deliver for investors regardless of the challenges ahead.
The stock you can't afford to ignore in 2014
AstraZeneca and Eli Lilly might be facing uncertain futures, but despite the market's huge run-up in 2013, there are still tons of great untapped opportunities waiting for investors among the many stocks you can find. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article The Biggest Victims of the Patent Cliff in 2014 originally appeared on Fool.com.Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.